Bio-Rad Laboratories Inc (BIO-B)vsMedtronic PLC (MDT)
BIO-B
Bio-Rad Laboratories Inc
$365.08
0.00%
HEALTHCARE · Cap: $9.76B
MDT
Medtronic PLC
$90.96
-0.72%
HEALTHCARE · Cap: $116.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Medtronic PLC generates 1350% more annual revenue ($37.54B vs $2.59B). MDT leads profitability with a 13.9% profit margin vs 8.6%. BIO-B appears more attractively valued with a PEG of 1.21. MDT earns a higher WallStSmart Score of 68/100 (B-).
BIO-B
Hold47
out of 100
Grade: D+
MDT
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIO-B.
Margin of Safety
+3.7%
Fair Value
$94.43
Current Price
$90.96
$3.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 40.7% YoY
Generating 1.3B in free cash flow
Areas to Watch
ROE of 2.5% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Revenue declined 0.1%
Expensive relative to growth rate
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BIO-B
The strongest argument for BIO-B centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.
Bull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : BIO-B
The primary concerns for BIO-B are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 44.5x leaves little room for execution misses.
Bear Case : MDT
The primary concerns for MDT are PEG Ratio, Altman Z-Score.
Key Dynamics to Monitor
BIO-B carries more volatility with a beta of 1.07 — expect wider price swings.
MDT is growing revenue faster at 13.7% — sustainability is the question.
MDT generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDT scores higher overall (68/100 vs 47/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?